PMID- 28889246
OWN - NLM
STAT- MEDLINE
DCOM- 20180710
LR  - 20211204
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 135
IP  - 3
DP  - 2017 Dec
TI  - The preliminary radiogenomics association between MR perfusion imaging parameters 
      and genomic biomarkers, and their predictive performance of overall survival in 
      patients with glioblastoma.
PG  - 553-560
LID - 10.1007/s11060-017-2602-x [doi]
AB  - The radiogenomics association of neovascularization is important for overall 
      survival (OS) in glioblastoma patients and remains unclear. The purpose of this 
      study is to assess the association between MR perfusion imaging derived 
      parameters and genomic biomarkers of glioblastoma, and to evaluate their 
      prognostic value. This retrospective study enrolled 41 patients with newly 
      diagnosed glioblastoma. The mean and maximal relative cerebral blood volume 
      (rCBV) ratio (rCBV(mean) and rCBV(max)), derived from MR perfusion weighted 
      imaging, of the enhancing tumor, as well as maximal rCBV ratio of peri-enhancing 
      tumor area (rCBV(peri-tumor)) were measured. The ki-67 labeling index, mammalian 
      target of rapamycin (mTOR) activation, epidermal growth factor receptor (EGFR) 
      amplification, isocitrate dehydrogenase (IDH) mutation and TP53 were assessed. 
      There was a significant correlation between rCBV(max) and mTOR based on Pearson's 
      correlations with Benjamini-Hochberg adjustment for controlling false discovery 
      rate, p = 0.047. The rCBV(peri-tumor) showed significant correlation with mTOR 
      (p = 0.0183) after adjustment of gender and EGFR status. The mean 
      rCBV(peri-tumor) value of the patients with OS shorter than 14 months was 
      significantly higher than patients with OS longer than 14 months, p = 0.002. The 
      rCBV(peri-tumor) and age were the two strongest predictors of OS (hazard 
      ratio = 1.29 and 1.063 respectively) by Cox regression analysis. This study 
      showed that hemodynamic abnormalities of glioblastoma were associated with 
      genomics activation status of mTOR-EGFR pathway, however, the radiogenomics 
      associations are different in enhancing and peri-enhancing area of glioblastoma. 
      The rCBV(peri-tumor) has better prognostic value than genomic biomarkers alone.
FAU - Liu, Xiang
AU  - Liu X
AUID- ORCID: 0000-0002-5172-9083
AD  - Department of Imaging Sciences, University of Rochester Medical Center, 601 
      Elmwood Avenue, PO Box 648, Rochester, NY, 14642-8638, USA. 
      Xiang_Liu@URMC.Rochester.edu.
FAU - Mangla, Rajiv
AU  - Mangla R
AD  - Department of Imaging Sciences, University of Rochester Medical Center, 601 
      Elmwood Avenue, PO Box 648, Rochester, NY, 14642-8638, USA.
FAU - Tian, Wei
AU  - Tian W
AD  - Department of Imaging Sciences, University of Rochester Medical Center, 601 
      Elmwood Avenue, PO Box 648, Rochester, NY, 14642-8638, USA.
FAU - Qiu, Xing
AU  - Qiu X
AD  - Department of Biostatistics and Computational Biology, University of Rochester 
      Medical Center, Rochester, NY, USA.
FAU - Li, Dongmei
AU  - Li D
AD  - Clinical and Translational Research and Public Health Sciences, University of 
      Rochester Medical Center, Rochester, NY, USA.
FAU - Walter, Kevin A
AU  - Walter KA
AD  - Department of Neurosurgey, University of Rochester Medical Center, Rochester, NY, 
      USA.
FAU - Ekholm, Sven
AU  - Ekholm S
AD  - Department of Imaging Sciences, University of Rochester Medical Center, 601 
      Elmwood Avenue, PO Box 648, Rochester, NY, 14642-8638, USA.
FAU - Johnson, Mahlon D
AU  - Johnson MD
AD  - Department of Pathology, University of Rochester Medical Center, Rochester, NY, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20170909
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Ki-67 Antigen)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain/*diagnostic imaging/pathology
MH  - Brain Neoplasms/*diagnostic imaging/*genetics/pathology/therapy
MH  - Cerebrovascular Circulation
MH  - ErbB Receptors/genetics
MH  - Female
MH  - Genetic Association Studies
MH  - Glioblastoma/*diagnostic imaging/*genetics/pathology/therapy
MH  - Humans
MH  - Isocitrate Dehydrogenase/genetics
MH  - Ki-67 Antigen/genetics
MH  - *Magnetic Resonance Imaging/methods
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - TOR Serine-Threonine Kinases/genetics
MH  - Tumor Suppressor Protein p53/genetics
OTO - NOTNLM
OT  - Brain
OT  - Glioblastoma
OT  - Perfusion weighted imaging
OT  - Radiogenomics
OT  - mTOR-EGFR pathway
EDAT- 2017/09/11 06:00
MHDA- 2018/07/11 06:00
CRDT- 2017/09/11 06:00
PHST- 2017/03/17 00:00 [received]
PHST- 2017/08/20 00:00 [accepted]
PHST- 2017/09/11 06:00 [pubmed]
PHST- 2018/07/11 06:00 [medline]
PHST- 2017/09/11 06:00 [entrez]
AID - 10.1007/s11060-017-2602-x [pii]
AID - 10.1007/s11060-017-2602-x [doi]
PST - ppublish
SO  - J Neurooncol. 2017 Dec;135(3):553-560. doi: 10.1007/s11060-017-2602-x. Epub 2017 
      Sep 9.